Table 3.
Outcome measures by study arm at 12 months – AS TREATED Analyses (N=326)
| Usual Care (N=188 patients, 27 PCPs) N (%) |
CDSS (N=63 patients, 17 PCPs) N (%) |
CDSS Plus (N=75 patients, 21 PCPs) N (%) |
Total (N=326 patients, 65 PCPs) N (%) |
p-value | |
|---|---|---|---|---|---|
| Clinical Primary and Secondary Outcome | |||||
| Change in systolic blood pressure **(mm Hg), mean ± SD | −2.1 ± 18.2 | −3.9 ± 20.7 | −0.9 ± 18.1 | −2.2 ± 18.7 | 0.6 |
| Change in diastolic blood pressure ** (mm Hg), mean ± SD | −0.2 ± 10.4 | −1.3 ± 12.0 | 0.5 ± 9.0 | −0.3 ± 10.4 | 0.7 |
| Controlled blood pressure** (<140/90 mmHg) | 109 (65) | 43 (68) | 50 (67) | 202(66) | 0.9 |
| CKD Awareness - Process Outcome | |||||
| PCP awareness of CKD at study end | 88 (47) | 46 (73) | 52 (69) | 186 (57) | 0.002 |
| PCP New Awareness | 14 (16) | 18 (55) | 22 (52) | 54 (33) | <0.001 |
| Secondary Clinical Process outcomes | |||||
| ACEi/ARB use *** | 95 (51) | 35 (56) | 40 (53) | 170 (52) | 0.7 |
| ACEi/ARB initiation (new use) *** | 5 (7) | 5 (24) | 1 (5) | 11(10) | 0.04 |
| Statin therapy use *** | 112 (61) | 36 (59) | 44 (61) | 192 (61) | 0.9 |
| Statin therapy initiation (new use) *** | 3 (2) | 2 (3) | 2 (3) | 7 (2) | 0.7 |
| Diuretic use *** | 47 (25) | 16 (25) | 16 (21) | 79 (24) | 0.8 |
| Diuretic initiation (new use) | 5 (4) | 2 (7) | 0 | 7 (4) | 0.5 |
*
p-values account for clustering of patients within physicians.
**
Only out of those 306 patients with valid BP measure during study period (number missing BP: 20 Usual Care, 0 CDSS, 0 CDSS PLUS).
***
ACE/ARB, Statin therapy and Diuretic medication “use” includes only patients who are still on the medication by the end of the study period.